

Bone Therapeutics Appoints Thomas Lienard as Chief Business Officer

Gosselies, Belgium, 9 November 2015 - BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in the field of bone fracture repair and bone fracture prevention, today announces the appointment of Thomas Lienard as Chief Business Officer with immediate effect.

Mr Lienard (39) has over 15 years of national and international sales and marketing experience in the pharmaceutical industry. Prior to joining Bone Therapeutics, Mr Lienard worked at Lundbeck, where he acted as Managing Director for Belgium and Luxemburg and was vital to the launch of several products. He led a team of up to 80 employees, generating over EUR 50 million in sales. Before his position at Lundbeck, Mr Lienard worked at Eli Lilly and Company, where he held various positions in sales and marketing in Europe and the US, including Sales Director Belgium in 2010. Mr Lienard started his career in 1999 as consultant at McKinsey & Company.

Mr Lienard graduated from Solvay Brussels School of Economics and Management as Master in Business Engineering in 1999 and obtained a Master of Business Administration (MBA) from Harvard Business School in Boston in 2004. At Bone Therapeutics, Mr Lienard will assume responsibility for activities regarding business development, business operations and strategic planning.

Welcoming Thomas Lienard to the team, Enrico Bastianelli, CEO of Bone Therapeutics, said: *“Thomas will bring invaluable expertise to our team. His experience in sales and marketing will help to maximise the potential of Bone Therapeutics’ pipeline of innovative products as they advance towards market approval and commercialization.”*

Commenting on his appointment, Thomas Lienard said: *“I look forward to working with the team at Bone Therapeutics, a company with an innovative product pipeline underpinned by a solid scientific base. Following its IPO earlier this year and the establishment of its US headquarters, Bone Therapeutics is in an exciting phase of its development, and I am very pleased to have the opportunity to contribute to this.”*

-Ends-

About Bone Therapeutics

Bone Therapeutics is a leading biotechnology company specializing in the development of cell therapy products intended for bone fracture repair and fracture prevention. The current standard-of-care in this field involves major surgeries and long recovery periods. To overcome these problems, Bone Therapeutics is developing a range of innovative regenerative products containing osteoblastic/bone-forming cells, administrable via a minimally invasive percutaneous technique; a unique proposition in the market.

PREOB[®], Bone Therapeutics’ autologous bone cell product, is currently in pivotal Phase IIB/III clinical studies for two indications: osteonecrosis and non-union fractures, and in Phase II for severe osteoporosis. ALLOB[®], its allogeneic “off-the-shelf” bone cell product, is in Phase I/IIA for the treatment of delayed-

union fractures and lumbar fusion for degenerative disease of the spine. The Company also runs preclinical research programs and develops novel product candidates.

Founded in 2006, Bone Therapeutics is headquartered in Gosselies (South of Brussels, Belgium). Bone Therapeutics' regenerative products are manufactured to the highest GMP standards and are protected by a rich IP estate covering 11 patent families. Further information is available at www.bonetherapeutics.com.

For more information, please contact:

Bone Therapeutics SA

Tel: +32 (0)2 529 59 90

Enrico Bastianelli, Chief Executive Officer/ Wim Goemaere, Chief Financial Officer

investorrelations@bonetherapeutics.com

For Belgium and International Media Enquiries

Consilium Strategic Communications

Tel: +44 (0) 20 3709 5701

Amber Fennell, Jessica Hodgson, Lindsey Neville and Hendrik Thys

bonetherapeutics@consilium-comms.com

For French Media and Investor Enquiries

NewCap Investor Relations & Financial Communications

Tel: + 33 (0)2 44 71 94 94

Pierre Laurent, Louis-Victor Delouvrier and Nicolas Merigeau

bone@newcap.fr

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

